The content on this site is intended for healthcare professionals only
Dr Volker Heinemann presents data on the German phase III clinical trial FIRE-3 during a press conference at the 2013 ASCO Annual Meeting in Chicago.
The trial reported that first-line cetuximab plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared with bevacizumab plus FOLFIRI.
The targeted drugs cetuximab and bevacizumab, both in combination with chemotherapy, are approved and commonly used as initial therapy but, until this study, it has been unclear which approach is better for patients with non-mutated forms of the KRAS gene.
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Research highlights in gastrointestinal tumours
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Immunotherapy significantly increases the number of patients free from bowel cancer
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
